Fitlife Brands, Inc.: Form 10-Q for the period ended Sep 30, 2021
Filed with the SEC on Nov 12, 2021 and accepted by EDGAR at Nov 12, 2021, 08:01 ET.
Management's discussion and analysis
As filed, 31,438 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and the related notes appearing elsewhere in this Quarterly Report on Form 10-Q (this "Quarterly Report"). This discussion and analysis may contain forward-looking statements based on assumptions about our future business.
Overview
FitLife Brands, Inc. (the “Company”) is a national provider of innovative and proprietary nutritional supplements for health-conscious consumers marketed under the following brand names: (i) NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, and Metis Nutrition (together, “NDS Products”); and (ii) iSatori, BioGenetic Laboratories, and Energize (together, “iSatori Products”). The Company distributes the NDS Products principally through franchised General Nutrition Centers, Inc. (“GNC”) stores located both domestically and internationally, and, with the launch of Metis Nutrition, through corporate GNC stores in the United States. The iSatori Products are sold through more than 17,000 retail locations, which include specialty, mass, and online.
FitLife Brands is headquartered in Omaha, Nebraska. For more information on the Company, please go to www.fitlifebrands.com (http://www.fitlifebrands.com). The Company’s common Stock, par value $0.01 per share (“Common Stock”), trades under the symbol “FTLF” on the OTCQX market.
Recent Developments
Nutrology Asset Purchase
On April 7, 2021, the Company purchased substantially all of the assets of Triple Impact Corporation, a New Jersey corporation doing business as Nutrology, a nutritional supplement company catering to consumers who prioritize all-natural and plant-based nutritional supplements. See Note 4 for additional detail regarding the acquisition.
Tax Benefits Preservation Plan
On February 26, 2021, the board of directors (the “Board”) of the Company declared a dividend distribution of one right (a “Right”) for each outstanding share of Common Stock to stockholders of record at the close of business on February 26, 2021 (the “Record Date”). Each Right entitles its holder, under the circumstances described below, to purchase from the Company one one-thousandth of a share of Series B Junior Participating Preferred Stock of the Company, par value $0.01 per share (the “Series B Preferred”), at an exercise price of $100.00 per Right, subject to adjustment. The description and terms of the Rights are set forth in the tax benefits preservation plan (the “Tax Benefits Preservation Plan”), dated as of February 26, 2021, between the Company and Colonial Stock, as rights agent (and any successor rights agent, the “Rights Agent”).
The Company adopted the Tax Benefits Preservation Plan in order to protect shareholder value against a possible limitation on the Company’s ability to use its net operating losses (“NOLs”) and certain other tax benefits to reduce potential future U.S. federal income tax obligations. The NOLs are a valuable asset to the Company, which may inure to the benefit of the Company and its stockholders. However, if the Company experiences an “ownership change,” as defined in Section 382 of the Internal Revenue Code (the “IRC”), its ability to fully utilize the NOLs and certain other tax benefits will be substantially limited and the timing of the usage of the NOLs and such other benefits could be substantially delayed, which could significantly impair the value of those assets. Generally, an “ownership change” occurs if the percentage of the Company’s stock owned by one or more of its “five-percent shareholders” (as such term is defined in Section 382 of the IRC) increases by more than 50 percentage points over the lowest percentage of stock owned by such stockholder or stockholders at any time over a three-year period. The Tax Benefits Preservation Plan is intended to prevent against such an “ownership change” by deterring any person or group from acquiring beneficial ownership of 4.99% or more of the Company’s securities.
Share Repurchase Plan
On August 16, 2019, the Company's Board authorized management to repurchase up to $500,000 of the Company's Common Stock over the next 24 months (the "Share Repurchase Program"), which Share Repurchase Program was previously reported on the Company's Current Report on Form 8-K filed August 20, 2019. On September 23, 2019, the Board approved an amendment to the Company’s Share Repurchase Program to increase the repurchase of up to $1,000,000 of the Company's Common Stock, its Series A Convertible Preferred Stock, par value $0.01 per share ("Series A Preferred"), and warrants to purchase shares of the Company's Common Stock ("Warrants"), over the next 24 months, at a purchase price, in the case of Common Stock, equal to the fair market value of the Company's Common Stock on the date of purchase, and in the case of Series A Preferred and Warrants, at a purchase price determined by management, with the exact date and amount of such purchases to be determined by management. On November 6, 2019, the Company’s Board of Directors amended the previously approved Share Repurchase Program to increase the amount of authorized repurchases to $2.5 million. On February 1, 2021, the Board approved an additional amendment to the previously authorized Share Repurchase Program. Under the terms of the amendment, the Company is authorized to repurchase up to $5.0 million. All other terms of the Share Repurchase Program remain unchanged.
The Company intends to conduct its Share Repurchase Program in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Repurchases may be made at management's discretion from time to time in the open market or through privately negotiated transactions. The Company may suspend or discontinue the Share Repurchase Program at any time, and may thereafter reinstitute purchases, all without prior announcement.
During the three months ended September 30, 2021, the Company did not repurchase any Securities under the Share Repurchase Program.
| Total number of shares purchased | Average price paid per share | Total number of shares purchased as part of publicly announced programs | Dollar value of shares that may yet be purchased | |
|---|---|---|---|---|
| First quarter ended March 31, 2021 | - | $- | - | $3,610,917 |
| Second quarter ended June 30, 2021 | 9,023 | $28.50 | 9,023 | $3,169,917 |
| Third quarter ended September 30, 2021 | - | $- | - | $3,169,917 |
| Subtotal | 9,023 | $28.50 | 9,023 | $3,169,917 |
COVID-19 Pandemic
The COVID-19 pandemic has had an effect on the Company’s employees, business and operations and those of its customers, vendors and business partners. In this respect, the temporary or permanent closure of some of our retail partners’ store locations and the stay-at-home orders that occurred early in the pandemic negatively affected our results from operations, although much of the impact has been offset by an increase in revenue attributable to online sales, and increased sales during the most recent quarter. Our future financial position and operating results could be materially and adversely affected in the event that a resurgence of COVID-19 cases leads to new stay-at-home orders and/or further disruptions in both our supply chain and manufacturing lead-times, which could lower demand for the Company’s products and/or prevent the Company from producing and delivering its products in a timely manner, although the extent of these effects cannot be determined at this time. The Company expects to continue to assess the evolving impact of the COVID-19 pandemic and intends to make adjustments to its business and operations accordingly.
CARES Act
The Coronavirus Aid, Relief, and Economic Security Act ("CARES Act") was enacted on March 27, 2020 in the United States. On April 27, 2020, the Company received proceeds from a loan in the amount of $449,700 from its lender, CIT Bank, N.A. (the “PPP Lender”), pursuant to approval by the U.S. Small Business Administration (the “SBA”) for the PPP Lender to fund the Company’s request for a loan under the SBA’s Paycheck Protection Program (“PPP Loan”) created as part of the recently enacted CARES Act administered by the SBA (the “Loan Agreement”). In accordance with the requirements of the CARES Act, the Company used the proceeds from the PPP Loan primarily for payroll costs, covered rent payments, and covered utilities during the eight-week period commencing on the date of loan approval. The PPP Loan was scheduled to mature on April 27, 2022, had a 1.0% interest rate, and was subject to the terms and conditions applicable to all loans made pursuant to the Paycheck Protection Program as administered by the SBA under the CARES Act. The Company was informed by the PPP Lender and the SBA that the full amount of principal and accrued interest of the PPP Loan was forgiven on January 15, 2021.
The CARES Act permits employers to defer payment of the employer portion of payroll taxes owed on wages paid through December 31, 2020 for a period of up to two years. Through December 31, 2020, the Company deferred payment of $77,000, which amount has been expensed and is included in accrued liabilities.
Results of Operations
Comparison of the three and nine months ended September 30, 2021 to the three and nine months ended September 30, 2020
| Three months ended September 30, 2021 | September 30, 2020 | Change% | Nine months ended September 30, 2021 | September 30, 2020 | Change% | |||
|---|---|---|---|---|---|---|---|---|
| Revenue | $6,705,000 | $6,923,000 | $(218,000) | -3% | $21,004,000 | $15,814,000 | $5,190,000 | 33% |
| Cost of goods sold | (3,760,000) | (4,061,000) | 301,000 | -7% | (11,421,000) | (8,896,000) | (2,525,000) | 28% |
| Gross profit | 2,945,000 | 2,862,000 | 83,000 | 3% | 9,583,000 | 6,918,000 | 2,665,000 | 39% |
| Operating expenses | (1,514,000) | (1,202,000) | (312,000) | 26% | (4,696,000) | (4,064,000) | (632,000) | 16% |
| Income from operations | 1,431,000 | 1,660,000 | (229,000) | -14% | 4,887,000 | 2,854,000 | 2,033,000 | 71% |
| Other income (expense) | 7,000 | 2,000 | 5,000 | 250% | 471,000 | 63,000 | 408,000 | 648% |
| Provision for income tax | (313,000) | (17,000) | (296,000) | 1741% | (1,041,000) | 64,000 | 1,105,000 | n/a |
| Net income | $1,125,000 | $1,645,000 | $(520,000) | -32% | $4,317,000 | $2,981,000 | $1,336,000 | 45% |
-18-
Net Sales. Revenue for the three months ended September 30, 2021 decreased to $6,705,000 as compared to $6,923,000 for the three months ended September 30, 2020. Online revenue during the quarter increased 39.8%. Wholesale revenue declined 12.2% driven by higher than normal purchases by GNC during the three months ended September 30, 2020 as it restocked following its bankruptcy filing.
Revenue for the nine months ended September 30, 2021 increased 33% to $21,004,000 as compared to $15,814,000 for the nine months ended September 30, 2020. Online revenue increased 57.5% and wholesale revenue increased 26.6% relative to the same nine-month period during 2020. The increase in revenue for the nine-month period ended September 30, 2021 compared to the prior nine-month period is principally due to the closure of some of our retail partners’ store locations and the stay-at-home orders during 2020 caused by the COVID-19 pandemic, continued organic growth in our wholesale and online businesses, and the acquisition of Nutrology.
Online revenue during the three and nine months ended September 30, 2021 was approximately 25% and 24% of total revenue, respectively, compared to approximately 17% and 20% of total revenue during the three and nine months ended September 30, 2020.
Cost of Goods Sold. Cost of goods sold for the three months ended September 30, 2021 decreased to $3,760,000 as compared to $4,061,000 for the three months ended September 30, 2020, with the decline primarily attributable to lower revenue.
Cost of goods sold for the nine months ended September 30, 2021 increased to $11,421,000 as compared to $8,896,000 for the nine months ended September 30, 2020, with the increase primarily attributable to higher revenue.
Gross Profit. Gross profit for the three months ended September 30, 2021 increased to $2,945,000 as compared to $2,862,000 for the three months ended September 30, 2020. The increase during the three-month period is principally attributable to a higher percentage of online sales during 2021 compared to the same period in 2020. Gross margin for the three months ended September 30, 2021 increased to 43.9% compared to 41.3% during the same period last year, which more than offset the effect of the decline in wholesale revenue during the quarter.
Gross profit for the nine months ended September 30, 2021 increased to $9,583,000 as compared to $6,918,000 for the nine months ended September 30, 2020. The increase was primarily attributable to higher revenue and a greater proportion of higher margin online revenue during 2021 compared to the same period in 2020. Gross margin for the nine months ended September 30, 2021 increased to 45.6% compared to 43.7% for the same period last year.
General and Administrative Expense. General and administrative expense for the three months ended September 30, 2021 increased to $891,000 as compared to $684,000 for the three months ended September 30, 2020. For the nine-month period ended September 30, 2021, general and administrative expense increased to $2,665,000 from $2,419,000 during the same period in the prior year. The increases for the three- and nine-month periods primarily reflect a temporary increase in consulting expense.
Selling and Marketing Expense. Selling and marketing expense for the three months ended September 30, 2021 increased to $605,000 as compared to $509,000 for the three months ended September 30, 2020. Selling and marketing expense for the nine months ended September 30, 2021 increased to $1,990,000 as compared to $1,614,000 for the nine months ended September 30, 2020. The increases in both the three- and nine-month periods ended September 30, 2021 reflect higher co-operative marketing expense paid to one of our wholesale partners. The Company anticipates that this higher level of marketing expense, which is fully funded by wholesale price increases, will continue for the foreseeable future.
Depreciation and Amortization Expense. Depreciation and amortization expense for the three months ended September 30, 2021 increased to $18,000 as compared to $9,000 for the three months ended September 30, 2020. Depreciation and amortization expense for the nine months ended September 30, 2021 increased to $41,000 as compared to $31,000 for the nine months ended September 30, 2020. The increases for the three- and nine-month periods are primarily due to the amortization of intangibles acquired in the Nutrology business combination.
Net Income Loss. We generated net income of $1,125,000 for the three-month period ended September 30, 2021 as compared to a net income of $1,645,000 for the three months ended September 30, 2020. The decline in net income for the quarter ended September 30, 2021 was primarily driven by income tax expense, which is non-cash due to the Company’s net operating loss carryforwards, and higher operating expenses.
We generated a net income of $4,317,000 for the nine-month period ended September 30, 2021 as compared to a net income of $2,981,000 for the nine months ended September 30, 2020. The increase for the and nine-month period ended September 30, 2021 was primarily due to higher revenues and higher gross margins.
Non-GAAP Measures
The financial presentation below contains certain financial measures defined as “non-GAAP financial measures” by the SEC, including non-GAAP EBITDA and adjusted non-GAAP EBITDA. These measures may be different from non-GAAP financial measures used by other companies. The presentation of this financial information, which is not prepared under any comprehensive set of accounting rules or principles, is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in this Quarterly Report in accordance with GAAP.
As presented below, non-GAAP EBITDA excludes interest, income taxes, and depreciation and amortization. Adjusted non-GAAP EBITDA excludes, in addition to interest, taxes, depreciation and amortization, equity-based compensation and non-recurring gains or losses. The Company believes the non-GAAP measures provide useful information to both management and investors by excluding certain expense and other items that may not be indicative of its core operating results and business outlook. The Company believes that the inclusion of non-GAAP measures in the financial presentation below allows investors to compare the Company’s financial results with the Company’s historical financial results and is an important measure of the Company’s comparative financial performance.
(Unaudited)
(Unaudited)
(Unaudited)
(Unaudited)
| For the three months ended September 30, 2021 | 2020 | For the nine months ended September 30, 2021 | 2020 | |
|---|---|---|---|---|
| Net income | $1,125,000 | $1,645,000 | $4,317,000 | $2,981,000 |
| Interest expense (income) | (7,000) | (2,000) | (18,000) | 7,000 |
| Provision (benefit) for income taxes | 313,000 | 17,000 | 1,041,000 | (64,000) |
| Depreciation and amortization | 18,000 | 9,000 | 41,000 | 31,000 |
| EBITDA | 1,449,000 | 1,669,000 | 5,381,000 | 2,955,000 |
| Non-cash and non-recurring adjustments | ||||
| Stock compensation expense | 107,000 | 19,000 | 345,000 | 69,000 |
| Non-recurring losses (gains) | - | - | (453,000) | (70,000) |
| Adjusted EBITDA | $1,556,000 | $1,688,000 | $5,273,000 | $2,954,000 |
Liquidity and Capital Resources
At September 30, 2021, we had positive working capital of approximately $12,287,000, compared to $7,744,000 at December 31, 2020. Our principal sources of liquidity at September 30, 2021 consisted of $8,617,000 of cash and $1,846,000 of accounts receivable.
On September 24, 2019, the Company entered into a Revolving Line of Credit Agreement (the “Line of Credit Agreement”) with Mutual of Omaha Bank (the “Lender”), subsequently acquired by CIT Bank N.A., providing the Company with a $2.5 million revolving line of credit (the “Line of Credit”). The Line of Credit allows the Company to request advances thereunder and to use the proceeds of such advances for working capital purposes until the Maturity Date, or unless renewed at maturity upon approval by the Company’s Board and the Lender. The Line of Credit is secured by all assets of the Company.
Advances drawn under the Line of Credit bear interest at an annual rate of the one-month LIBOR rate plus 2.75%, and each advance will be payable on the Maturity Date with the interest on outstanding advances payable monthly. The Company may, at its option, prepay any borrowings under the Line of Credit, in whole or in part at any time prior to the Maturity Date, without premium or penalty.
On March 20, 2020, the Lender advanced the Company $2.5 million under the Line of Credit, which amount was repaid on April 29, 2020. The advance was intended to provide the Company with additional liquidity given the uncertainty regarding the timing of collection of certain accounts receivable and in anticipation of an expected negative impact on sales to GNC and our other wholesale customers resulting from the COVID-19 outbreak.
On August 4, 2021, the Company and the Lender amended the Line of Credit Agreement to extend the Maturity Date to September 23, 2022. All other terms of the Line of Credit Agreement remain unchanged.
On April 27, 2020, the Company received proceeds from a loan in the amount of $449,700 from the PPP Lender, pursuant to approval by the SBA for the Lender to fund the Company’s request for the PPP Loan created as part of the recently enacted CARES Act administered by the SBA. In accordance with the requirements of the CARES Act, the Company used the proceeds from the PPP Loan primarily for payroll costs, covered rent payments, and covered utilities during the eight-week period commencing on the date of loan approval. The PPP Loan was scheduled to mature on April 27, 2022, had a 1.0% interest rate, and was subject to the terms and conditions applicable to all loans made pursuant to the Paycheck Protection Program as administered by the SBA under the CARES Act. The Company did not provide any collateral or guarantees for the PPP Loan, nor did the Company pay any fees to obtain the PPP Loan. The Company was informed by the PPP Lender and the SBA that the full amount balance of the PPP Loan, including accrued interest, was forgiven on January 15, 2021.
The Company has historically financed its operations primarily through cash flow from operations and equity and debt financings. The Company has also provided for its cash needs by issuing Common Stock, options and warrants for certain operating costs, including consulting and professional fees. The Company currently anticipates that cash derived from operations and existing cash resources, along with available borrowings under the Line of Credit, will be sufficient to provide for the Company’s liquidity for the next twelve months.
The Company is dependent on cash flow from operations and amounts available under the Line of Credit to satisfy its working capital requirements. No assurances can be given that cash flow from operations and/or the Line of Credit will be sufficient to provide for the Company’s liquidity for the next twelve months. Should the Company be unable to generate sufficient revenue in the future to achieve positive cash flow from operations, and/or should capital be unavailable under the terms of the Line of Credit, additional working capital will be required. Management currently has no intention to raise additional working capital through the sale of equity or debt securities and believes that the cash flow from operations and available borrowings under the Line of Credit will provide sufficient capital necessary to operate the business over the next twelve months. In the event the Company fails to achieve positive cash flow from operations, additional capital is unavailable under the terms of the Line of Credit, and management is otherwise unable to secure additional working capital through the issuance of equity or debt securities, the Company’s business would be materially and adversely harmed.
Cash Provided by Operations. Cash provided by operating activities for the nine months ended September 30, 2021 was $3,200,000, as compared to cash provided by operations of $3,475,000 for the nine months ended September 30, 2020.
Cash Used in Investing Activities. Cash used in investing activities for the nine months ended September 30, 2021 was $529,000, as compared to cash used by investing activities of $0 for the nine months ended September 30, 2020.
Cash Provided by (Used in) Financing Activities. Cash used in financing activities for the nine months ended September 30, 2021 was $(390,000) as compared to cash provided by financing activities of $350,000 during the nine months ended September 30, 2020.
Critical Accounting Policies and Estimates
Our discussion and analysis of financial condition and results of operations is based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP"). The preparation of these consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, expense, and related disclosure of contingent assets and liabilities. We evaluate, on an on-going basis, our estimates and judgments, including those related to the useful life of the assets. We base our estimates on historical experience and assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.
The methods, estimates and judgments we use in applying our most critical accounting policies have a significant impact on the results that we report in our consolidated financial statements. The Securities and Exchange Commission (the "SEC") considers an entity’s most critical accounting policies to be those policies that are both most important to the portrayal of a company’s financial condition and results of operations and those that require management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about matters that are inherently uncertain at the time of estimation. For a more detailed discussion of the accounting policies of the Company, see Note 3 of the Notes to the Condensed Consolidated Financial Statements included in this Quarterly Report, “Summary of Significant Accounting Policies”.
We believe the following critical accounting policies, among others, require significant judgments and estimates used in the preparation of our consolidated financial statements.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) the disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published, and (iii) the reported amount of net sales and expense recognized during the periods presented. Adjustments made with respect to the use of estimates often relate to improved information not previously available. Uncertainties with respect to such estimates and assumptions are inherent in the preparation of financial statements; accordingly, actual results could differ from these estimates.
These estimates and assumptions also affect the reported amounts of accounts receivable, inventories, goodwill, revenue, costs and expense and valuations of long-term assets, allowance for deferred tax assets and equity instruments issued for services during the reporting period. Management evaluates these estimates and assumptions on a regular basis. Actual results could differ from those estimates.
Goodwill
In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Accounting for Goodwill Impairment. ASU 2017-04 removes Step 2 of the goodwill impairment test, which required a hypothetical purchase price allocation. A goodwill impairment will now be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. This update also eliminated the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. The Company adopted ASU 2017-04 on January 1, 2020 and applied the requirements prospectively.
While we have concluded that a triggering event did not occur during the three or nine months ended September 30, 2021, a worsening of the severity of the COVID-19 pandemic could result in future goodwill impairment charges. We will continue to monitor the effects of the COVID-19 pandemic’s impact on our business, and review for impairment indicators as necessary in the upcoming months.
Revenue Recognition
The Company’s revenue is comprised of sales of nutritional supplements to consumers, primarily through GNC stores.
The Company accounts for revenues in accordance with Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers. The underlying principle of ASC 606 is to recognize revenue to depict the transfer of goods or services to customers at the amount expected to be collected. ASC 606 creates a five-step model that requires entities to exercise judgment when considering the terms of contract(s), which includes (1) identifying the contract(s) or agreement(s) with a customer, (2) identifying our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied. Under ASC 606, revenue is recognized when performance obligations under the terms of a contract are satisfied, which occurs for the Company upon shipment or delivery of products or services to our customers based on written sales terms, which is also when control is transferred. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring the products or services to a customer.
All products sold by the Company are distinct individual products and consist of nutritional supplements and related supplies. The products are offered for sale solely as finished goods, and there are no performance obligations required post-shipment for customers to derive the expected value from them.
Control of products we sell transfers to customers upon shipment from our facilities, and the Company’s performance obligations are satisfied at that time. Shipping and handling activities are performed before the customer obtains control of the goods and therefore represent a fulfillment activity rather than promised goods to the customer. Payments for sales are generally made by check, credit card, or wire transfer. Historically the Company has not experienced any significant payment delays from customers.
For direct-to-consumer sales, the Company allows for returns within 30 days of purchase. Our wholesale customers, such as GNC, may return purchased products to the Company under certain circumstances, which include expired or soon-to-be-expired products located in GNC corporate stores or at any of its distribution centers, and products that are subject to a recall or that contain an ingredient or ingredients that are subject to a recall by the U.S. Food and Drug Administration.
A right of return does not represent a separate performance obligation, but because customers are allowed to return products, the consideration to which the Company expects to be entitled is variable. Upon evaluation of returns, the Company determined that less than 5% of products are returned, and therefore believes it is probable that such returns will not cause a significant reversal of revenue in the future. We assess our contracts and the reasonableness of our conclusions on a quarterly basis.
The Company’s revenue recognition, sales, and returns policies and experience for Nutrology are consistent with those of the Company’s other brands.
Recent Accounting Pronouncements
See Note 3 of the Condensed Consolidated Financial Statements included in this Quarterly Report for a description of recent accounting pronouncements believed by management to have a material impact on our present or future financial statements.
Market risk
As filed, 1,579 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Our business is currently conducted principally in the United States. As a result, our financial results are not materially affected by factors such as changes in foreign currency exchange rates or economic conditions in foreign markets. We do not engage in hedging transactions to reduce our exposure to changes in currency exchange rates although, as the geographical scope of our business broadens, we may do so in the future.
Our exposure to risk for changes in interest rates relates primarily to any borrowings under our existing Line of Credit, and our investments in short-term financial instruments. As of September 30, 2021, the Company had a zero balance under its existing Line of Credit.
Investments of our existing cash balances in both fixed rate and floating rate interest-earning instruments carry some interest rate risk. The fair value of fixed rate securities may fall due to a rise in interest rates, while floating rate securities may produce less income than expected if interest rates fall. Partly as a result of this, our future interest income will vary due to changes in interest rates and we may suffer losses in principal if we are forced to sell securities that have fallen in estimated fair value due to changes in interest rates. However, as substantially all of our cash equivalents consist of bank deposits and short-term money market instruments, we do not expect any material change with respect to our net income as a result of an interest rate change.
We do not hold any derivative instruments and do not engage in any hedging activities.
Controls and procedures
As filed, 4,054 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
(a) Evaluation of Disclosure Controls and Procedures
We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures were designed to provide reasonable assurance that the controls and procedures would meet their objectives. As required by SEC Rule 13a-15(b), our Chief Executive Officer and Chief Financial Officer carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level.
Our Chief Executive Officer and Chief Financial Officer are responsible for establishing and maintaining adequate internal control over our financial reporting. In order to evaluate the effectiveness of internal control over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act, management has conducted an assessment, including testing, using the criteria in Internal Control — Integrated Framework, issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”). Our system of internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Management has used the framework set forth in the report entitled Internal Control-Integrated Framework published by the COSO to evaluate the effectiveness of our internal control over financial reporting. Based on this assessment, our Chief Executive Officer and Chief Financial Officer have concluded that our internal control over financial reporting was effective as of September 30, 2021. This Quarterly Report does not include an attestation report of the Company's independent registered public accounting firm regarding internal control over financial reporting. Management's report was not subject to attestation by the Company's independent registered public accounting firm pursuant to rules of the SEC that permit the Company to provide only management's report in this Quarterly Report. There has been no change in our internal controls over financial reporting during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting.
(b) Changes in Internal Controls Over Financial Reporting
The Company's Chief Executive Officer and Chief Financial Officer have determined that there have been no changes in our internal controls over financial reporting or in other factors that could materially affect, or are reasonably likely to affect, our internal controls over financial reporting during the quarter ended September 30, 2021. There have not been any significant changes in the Company’s critical accounting policies identified since the Company filed its Annual Report on Form 10-K for the year ended December 31, 2020.
PART II
OTHER INFORMATION
Risk factors
As filed, 2,091 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Our results of operations and financial condition are subject to numerous risks and uncertainties described in our Annual Report on Form 10-K for our fiscal year ended December 31, 2020, filed on March 26, 2021. Except as set forth below, management is not aware of any material changes to the risk factors discussed in Part 1, Item 1A, of the Annual Report on Form 10-K for the year ended December 31, 2020. You should carefully consider these risk factors in conjunction with the other information contained in this Quarterly Report. Should any of these risks materialize, our business, financial condition and future prospects could be negatively impacted.
COVID-19 has impacted global supply chains and such impacts have impacted us and our third-party suppliers and could have a material adverse impact on us in the future.
The coronavirus (COVID-19) pandemic has had a material impact on global supply chains, including for certain raw materials imported from China, among other countries, that have had an impact on our third-party suppliers and our wholesale partners. As a result, we have had to increase purchases in certain raw materials and build finished goods inventory, especially in our best-selling products, to avoid, in addition to other consequences, stockouts. The extent to which the ongoing coronavirus continues to impact our operations, those of our third-party suppliers or our wholesale partners will depend on future developments, which are highly uncertain and cannot be predicted. If the public continues to avoid public spaces, including retail stores, or if we, or any of our third-party suppliers continue to encounter challenges in the supply chain for certain raw materials, or incur disruptions to our or their respective operations, facilities or stores, or if our wholesale partners’ retail stores were to partially or fully close due to the coronavirus, which has previously occurred in the case of certain GNC locations, then the manufacture, supply, distribution and sale of our products and our financial results could be adversely affected.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2021-07-01 to 2021-09-30 | $6.7m | us-gaap:Revenues |
| Revenue | 9 months2021-01-01 to 2021-09-30 | $21.0m | us-gaap:Revenues |
| Cost of revenue | 3 months2021-07-01 to 2021-09-30 | $3.8m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months2021-01-01 to 2021-09-30 | $11.4m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2021-07-01 to 2021-09-30 | $2.9m | us-gaap:GrossProfit |
| Gross profit | 9 months2021-01-01 to 2021-09-30 | $9.6m | us-gaap:GrossProfit |
| Operating income | 3 months2021-07-01 to 2021-09-30 | $1.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2021-01-01 to 2021-09-30 | $4.9m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2021-07-01 to 2021-09-30 | $313.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2021-01-01 to 2021-09-30 | $1.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2021-07-01 to 2021-09-30 | $1.1m | us-gaap:NetIncomeLoss |
| Net income | 9 months2021-01-01 to 2021-09-30 | $4.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2021-07-01 to 2021-09-30 | $0.93 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2021-01-01 to 2021-09-30 | $3.59 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2021-07-01 to 2021-09-30 | $1.02 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2021-01-01 to 2021-09-30 | $3.95 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2021-07-01 to 2021-09-30 | 1,204,524 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2021-01-01 to 2021-09-30 | 1,202,177 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2021-01-01 to 2021-09-30 | $3.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Share repurchases | 9 months2021-01-01 to 2021-09-30 | $444.0k | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2021-09-30 | $8.6m | us-gaap:Cash |
| Current assets | At period end2021-09-30 | $16.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2021-09-30 | $20.9m | us-gaap:Assets |
| Current liabilities | At period end2021-09-30 | $4.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2021-09-30 | $4.6m | us-gaap:Liabilities |
| Shareholders' equity | At period end2021-09-30 | $16.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001851734-21-000065. Last ingested by Listed: Oct 24, 2026, 15:09 ET. Listed shows no prices and gives no investment advice.